Conor Glynn

Conor Glynn

Total lobbying returns involving this official: 11

Connections GraphMethod Pie

Official Profile

Most Recent Title
Special Advisor to the Tanaiste
Most Recent Public Body
Department of the Taoiseach
First Seen
21 May 2025
Last Seen
21 January 2026

Observed Titles

Special AdviserSpecial AdvisorSpecial Advisor to the Tanaiste

Observed Public Bodies

Department of Foreign AffairsDepartment of the Taoiseach
All Lobbyists
Select methods...

Lobbying Records (Page 1 of 2)

Pfizer

2026-01-21

Intent: Ensure Ireland remains vocal against tariffs/ retaliatory tariffs on medicines and pharmaceutical ingredients; Ensure Ireland understands potential impacts of MFN policy and recognises the need for Ireland (and Europe) to appropriately value innovation closing the gap between Europe and the US; in Ireland specifically the Framework Supply Agreement and RSV immunisation

Details: Geopolitical polices in relation to tariffs and Most Favoured Nation (MFN) pricing

Methods
Meeting between Pfizer Global CFO and Tanaiste Simon Harris in the US - MeetingEmail

MSD

2026-01-15

Intent: To discuss with the Tánaiste and Minister for Finance Simon Harris (with IDA participation) the need to strengthen vaccine confidence, Ireland’s pro innovation policy environment, improve access to medicines, and elevate cardiovascular public health priorities across the EU, together with reaffirming MSD’s 50-year partnership with Ireland.

Details: Health Policy

Methods
EmailMeeting

MSD

2025-09-19

Intent: To support the work of the Irish Government on the establishment of a EU Pharma Task Force of Member States to support the pharmaceutical industry in the EU.

Details: EU Pharma Task Force

Methods
EmailMeeting

Pfizer

2025-09-19

Intent: To highlight our concerns about the inclusion of pharmaceuticals in tariffs, the timing for entry into force, and the need for a zero-tariff pathway that includes innovative medicines. ::To highlight the potential impact of Most Favoured Nation pricing for pharmaceuticals in the US and the need for further investment in innovative medicines in Europe that recognises the value of biopharmaceutical innovation

Details: Raise concern about the impact of potential tariffs and related geo-political issues related to the pharmaceutical industry and pricing of medicines globally

Methods
Pfizer CEO Albert Bourla met with Tánaiste Simon Harris in Dublin - MeetingEmailPhone call